Global Single-Molecule Real-Time Sequencing (SMRT) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Single-Molecule Real-Time Sequencing (SMRT) Market Segmentation, By Application (DNA Sequencing, RNA Sequencing, Epigenetics, Whole Genome Sequencing, and Others), Product (Consumable, Instrument, and Services), End-Users (Hospitals, Diagnostic Laboratories, Biopharmaceutical Companies, Academic Institutes and Research Centers, and Others) - Industry Trends and Forecast to 2032

Single-Molecule Real-Time Sequencing (SMRT) Market Size

• The global single-molecule real-time sequencing (SMRT) market size was valued at USD 2.88 billion in 2024 and is expected to reach USD 4.36 billion by 2032, at a CAGR of 5.30% during the forecast period
• The market growth is largely fuelled by the increasing adoption and technological advancements in next-generation sequencing platforms, with single-molecule real-time (SMRT) sequencing emerging as a prominent tool due to its long-read capability, high accuracy, and ability to detect epigenetic changes in real time
• Furthermore, rising demand for precision medicine, cancer genomics, and rare disease research is positioning SMRT sequencing as a preferred method for comprehensive genome analysis. These converging factors are accelerating the uptake of SMRT solutions, thereby significantly boosting the industry's growth

Single-Molecule Real-Time Sequencing (SMRT) Market Analysis

• Single-molecule real-time (SMRT) sequencing, a cutting-edge long-read sequencing technology, is becoming increasingly vital in genomics research, clinical diagnostics, and precision medicine due to its ability to provide high-throughput, highly accurate sequencing with epigenetic insight, real-time analysis, and minimal amplification bias
• The surging demand for advanced genomic technologies, increasing prevalence of genetic disorders and cancers, and expanding applications in transcriptomics and epigenetics are among the primary factors driving the adoption of SMRT sequencing across academic, clinical, and biopharmaceutical sectors
• North America dominated the single-molecule real-time sequencing (SMRT) market, with the largest revenue share of 50.70% in 2024, driven by strong R&D infrastructure, high healthcare spending, and the presence of leading biotechnology companies. The U.S. leads the regional growth due to continuous innovation, robust funding for genomics research, and early clinical integration of SMRT technologies
• Asia-Pacific is projected to witness the fastest growth in the single-molecule real-time sequencing (SMRT) market during the forecast period, with a CAGR of 14.8%, propelled by rising investment in genomics, government-backed precision medicine initiatives, and increasing access to advanced sequencing technologies in countries such as China, Japan, and India
• DNA sequencing segment dominated the single-molecule real-time sequencing (SMRT) market by application with a market share of 38.7% in 2024, driven by its critical role in clinical diagnostics, precision medicine, and large-scale genomic projects that require accurate and comprehensive genetic analysis

Report Scope and Single-Molecule Real-Time Sequencing (SMRT) Market Segmentation    

Single-Molecule Real-Time Sequencing (SMRT) Market Trends

“Advancing Genomics with Turn‑Key Long‑Read Platforms”

• A major and rapidly expanding trend in the global single‑molecule real‑time sequencing (SMRT) market is the move toward fully integrated, end‑to‑end sequencing workstations that bundle long‑read instruments with automated sample preparation and cloud‑native analysis pipelines, dramatically shortening the path from DNA extraction to actionable results

  • For instance, Pacific Biosciences’ Revio system couples on‑board compute with SMRT Link software, enabling users to launch assembly or variant‑calling workflows directly from the touchscreen and monitor HiFi read generation in real time—ideal for oncology panels, pharmacogenomics, and newborn screening

• Informatics suites now embed AI‑enhanced callers such as DeepConsensus and Google DeepVariant, which automatically refine read‑quality thresholds and deliver confidence‑scored variant reports, reducing reliance on specialized bioinformatics staff and accelerating clinical adoption
• Automated library‑prep modules from partners such as Hamilton Robotics and Roche KAPA streamline high‑molecular‑weight DNA handling for up to 96 samples per shift, trimming hands‑on time by more than 60 %—a critical enabler for large‑scale population genomics and rare‑disease studies
• Secure cloud deployment through collaborations with Amazon Web Services, DNAnexus, and Illumina Connected Analytics offers elastic storage, HIPAA‑compliant data management, and real‑time collaboration across distributed research teams, while built‑in LIMS connectivity supports CLIA and CAP accreditation
•  Demand for these streamlined, intelligent SMRT solutions is climbing across academic, biopharma, and diagnostic sectors as organizations pursue faster turnaround times, lower per‑genome costs, and comprehensive detection of structural variants and epigenetic modifications at scale

Single-Molecule Real-Time Sequencing (SMRT) Market Dynamics

Driver

“Growing Need for High-Resolution Genomics in Clinical and Research Settings”

• The increasing demand for high-throughput and high-resolution genomic analysis in both clinical diagnostics and research is a major driver of growth in the single-molecule real-time sequencing (SMRT) market. SMRT technology provides long-read capabilities, accurate detection of structural variants, and the ability to directly detect epigenetic modifications—features that are crucial in applications such as oncology, rare disease diagnostics, and metagenomics

  • For instance, in January 2024, Pacific Biosciences launched new high-capacity SMRT cells capable of generating even longer reads at lower costs, facilitating broader adoption in translational medicine and population-scale genomics. These advancements are expected to significantly boost market growth over the forecast period

• The push for personalized medicine, coupled with increased funding for genome research initiatives globally, is accelerating the adoption of SMRT sequencing in both developed and emerging markets
• Moreover, the growing utility of SMRT sequencing in single-cell analysis, full-length transcriptome sequencing, and microbial genome assembly makes it a preferred tool for researchers seeking high-fidelity genomic data
• The increasing collaboration between biotechnology firms and academic institutions, along with improvements in workflow automation and cloud-based bioinformatics solutions, is further propelling the market forward by reducing barriers to entry and enhancing accessibility

Restraint/Challenge

“High Capital Costs and Complexity of Data Interpretation”

• Despite its technical advantages, the high cost of acquiring and operating SMRT sequencing platforms remains a significant restraint, particularly for small research labs and institutions in low- and middle-income countries. Initial investment in equipment, consumables, and computational infrastructure can be prohibitive compared to short-read sequencing platforms

  • For instance, the cost of SMRT instruments such as Pacific Biosciences' Sequel IIe system, along with the need for high-quality DNA input and specialized personnel, has limited its broader adoption in resource-constrained settings

• Another major challenge is the complexity of data analysis. SMRT sequencing generates large volumes of data that require sophisticated bioinformatics pipelines for accurate interpretation. This can be a barrier for organizations lacking in-house computational expertise or access to high-performance computing resources
• Companies are addressing this through user-friendly software, cloud-based analysis platforms, and training programs, but gaps in standardization and bioinformatics capacity still persist
• To achieve more widespread use, particularly in clinical settings, the SMRT sequencing market will need to overcome these challenges through cost reduction strategies, simplified workflows, and enhanced support for data interpretation and regulatory compliance

Single-Molecule Real-Time Sequencing (SMRT) Market Scope

The market is segmented on the basis of application, product, and end-user.

• By Application

On the basis of application, the single-molecule real-time sequencing (SMRT) market is segmented into DNA sequencing, RNA sequencing, epigenetics, whole genome sequencing, and others. The DNA sequencing segment held the largest market revenue share of 38.7% in 2024, driven by its widespread application in clinical diagnostics, precision medicine, and microbial genomics. The long-read capabilities and high accuracy of SMRT technology make it ideal for detecting structural variants and complex genomic regions, which are often missed by short-read platforms.

The epigenetics segment is anticipated to witness the fastest growth rate of 20.1% from 2025 to 2032, fueled by the growing interest in understanding gene regulation mechanisms and the role of epigenetic modifications in diseases such as cancer and neurological disorders. SMRT sequencing's ability to detect base modifications directly, without requiring chemical treatment, enhances its value in epigenetic studies.

• By Product

On the basis of product, the single-molecule real-time sequencing (SMRT) market is segmented into consumables, instruments, and services. The consumables segment held the largest market revenue share of 51.7% in 2024, driven by the continuous and recurring demand for reagents, SMRT cells, and sample preparation kits across sequencing workflows. The growth of sequencing throughput and adoption across diverse applications ensures strong ongoing demand for consumables.

The services segment is expected to witness the fastest CAGR of 18.3% from 2025 to 2032, driven by the increasing trend of outsourcing sequencing and bioinformatics to specialized providers. Rising demand for high-quality data analysis, affordability, and faster turnaround times support growth in this segment.

• By End-User

On the basis of end-user, the single-molecule real-time sequencing (SMRT) market is segmented into hospitals, diagnostic laboratories, biopharmaceutical companies, academic institutes and research centers, and others. The academic institutes and research centers segment accounted for the largest market revenue share of 42.6% in 2024, owing to their significant involvement in genomics research, novel biomarker discovery, and the adoption of advanced sequencing platforms for large-scale studies.

The diagnostic laboratories segment is anticipated to witness the fastest CAGR of 19.5% from 2025 to 2032, driven by the increasing use of SMRT technology in clinical diagnostics for detecting rare genetic mutations, infectious diseases, and complex hereditary conditions. The growing demand for precision diagnostics and personalized medicine further propels this segment.

Single-Molecule Real-Time Sequencing (SMRT) Market Regional Analysis

• North America dominated the single-molecule real-time sequencing (SMRT) market with the largest revenue share of 50.70% in 2024, driven by substantial investments in genomics research, advanced healthcare infrastructure, and strong government support for precision medicine initiatives
• The region benefits from the presence of key industry players, cutting-edge research institutions, and widespread adoption of SMRT technology in clinical diagnostics, biopharmaceutical development, and academic research
• High awareness of genomics applications and increasing funding for personalized medicine contribute to the growing demand for SMRT platforms, making North America a leading market for innovative sequencing solutions across both research and clinical settings

U.S. Single-Molecule Real-Time Sequencing (SMRT) Market Insight

The U.S. single-molecule real-time sequencing (SMRT) market largest revenue share of 81% in 2024. This market is fueled by extensive investments in genomic research, a high prevalence of genetic disorders, and the increasing adoption of SMRT technology for long-read sequencing applications in complex genome assembly, structural variation detection, and epigenetic analysis. The strong presence of leading biotechnology and pharmaceutical companies, coupled with significant funding from government and private organizations for precision medicine initiatives, further propels the SMRT sequencing industry. The demand for highly accurate and comprehensive genomic data for personalized medicine and advanced diagnostics is a key driver.

Europe Single-Molecule Real-Time Sequencing (SMRT) Market Insight

The Europe single-molecule real-time sequencing (SMRT) market is projected to expand at a substantial CAGR from 2025 to 2032. This growth is primarily driven by increasing government and private funding for genomics research, the rising need for detailed genetic analysis in clinical diagnostics, and collaborative efforts in precision medicine across the continent. The expanding applications of long-read sequencing technologies, which provide more detailed and accurate insights into complex genetic information, further drive market growth.

U.K. Single-Molecule Real-Time Sequencing (SMRT) Market Insight

The U.K. single-molecule real-time sequencing (SMRT) market is anticipated to grow at a noteworthy CAGR during the forecast period. This growth is driven by strong government support for national genomics initiatives (such as Genomics England), a growing emphasis on personalized medicine, and the increasing demand for comprehensive genomic insights in both research and clinical settings. The U.K. holds a 6% revenue share within the broader European genome sequencing market, reflecting its significant contribution to regional advancements in genomic research and clinical adoption of SMRT technologies.

Germany Single-Molecule Real-Time Sequencing (SMRT) Market Insight

The Germany single-molecule real-time sequencing (SMRT) market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing investments in biomedical research, a robust pharmaceutical and biotechnology sector, and the demand for highly accurate and comprehensive genomic data. Germany accounts for 7% of the overall European genome sequencing market revenue, highlighting its pivotal role in advancing genomic technologies. The country's well-developed research infrastructure, combined with a strong emphasis on innovation in life sciences and a preference for high-quality, privacy-focused solutions, promotes the adoption of SMRT sequencing in complex disease studies and applied genomics.

Asia-Pacific Single-Molecule Real-Time Sequencing (SMRT) Market Insight

The Asia-Pacific single-molecule real-time sequencing (SMRT) market is poised to grow at the fastest CAGR of 14.8% during the forecast period of 2025 to 2032. This rapid growth is driven by increasing government investments in large-scale genomics projects, a vast and diverse population base with unique genetic variations, rising healthcare expenditure, and significant technological advancements in countries such as China, Japan, and India. As APAC emerges as a major hub for life science research and biotechnology, the increasing affordability and accessibility of SMRT components and systems are expanding to a wider research and clinical community.

China Single-Molecule Real-Time Sequencing (SMRT) Market Insight

The China single-molecule real-time sequencing (SMRT) market accounted for the largest market revenue share within Asia Pacific in 2024, often contributing a significant portion of the region's overall sequencing revenue. This leadership is attributed to the country's massive investments in life sciences, rapid expansion of biotechnology industries, and high rates of technological adoption in genomics. The push towards national precision medicine initiatives, large-scale genomic studies, and the availability of increasingly sophisticated SMRT options from strong domestic research and manufacturing capabilities are key factors propelling the market in China.

India Single-Molecule Real-Time Sequencing (SMRT) Market Insight

The India single-molecule real-time sequencing (SMRT) market is witnessing rapid growth during the forecast period. Increasing government and private funding for genomics research, a rising prevalence of genetic disorders, and expanding awareness about advanced sequencing solutions are key drivers. Government initiatives promoting indigenous research and diagnostic capabilities are accelerating adoption. The growing number of research institutions, pharmaceutical companies, and diagnostic laboratories, coupled with a focus on personalized healthcare and agricultural genomics, further bolster the market. India is emerging as both a significant consumer and an upcoming hub for SMRT technology applications across various research and clinical domains.

Single-Molecule Real-Time Sequencing (SMRT) Market Share

The single-molecule real-time sequencing (SMRT) industry is primarily led by well-established companies, including:

• PacBio (U.S.)
• Beijing Genomics Institute (BGI) (China)
• CeGaT GmbH (Germany)
• Eurofins Genomics (Luxembourg)
• Comprehensive Biomarker Center GmbH (Germany)
• Illumina, Inc. (U.S.)
• Macrogen (South Korea)
• Microsynth AG (Switzerland)
• SEQOMICS Ltd. (Germany)
• NABSYS (U.S.)
• DNAnexus, Inc. (U.S.)
• Genedata AG (Switzerland)
• BaseClear BV (Netherlands)

Latest Developments in Global Single-Molecule Real-Time Sequencing (SMRT) Market

• In April 2023, PacBio, a global leader in Single-Molecule Real-Time Sequencing (SMRT) technology based in the U.S., announced the launch of its latest SMRT sequencing platform aimed at increasing accuracy and throughput for genomic research. This advancement highlights PacBio’s commitment to pushing the boundaries of sequencing technology, enabling researchers worldwide to gain deeper insights into complex genomes with higher efficiency. By integrating innovative chemistry and software improvements, PacBio is reinforcing its leadership in the expanding global SMRT market
• In March 2023, Beijing Genomics Institute (BGI), headquartered in China, unveiled a new SMRT sequencing service tailored for clinical diagnostics and personalized medicine. This initiative emphasizes BGI’s dedication to providing accessible and precise genomic solutions, supporting the advancement of healthcare and biotech industries. The rollout of this service also reflects the growing demand for high-quality sequencing data in Asia-Pacific, bolstering BGI’s position in the competitive SMRT market
• In March 2023, Illumina, a U.S.-based genomic technology company, expanded its SMRT sequencing collaborations with pharmaceutical companies to accelerate drug discovery and biomarker development. These partnerships demonstrate Illumina’s strategic focus on leveraging SMRT sequencing for improving precision medicine and enhancing therapeutic pipelines. This move solidifies Illumina’s role as a key player driving innovation in the SMRT sequencing ecosystem
• In February 2023, Genedata AG, a Switzerland-based bioinformatics firm, announced the integration of advanced SMRT sequencing data analysis capabilities into its software platform. This enhancement is designed to streamline genomic data interpretation for researchers and biotech companies, improving accuracy and reducing analysis time. Genedata’s collaboration with SMRT sequencing providers underscores the growing importance of sophisticated bioinformatics solutions in maximizing the value of SMRT data
• In January 2023, Eurofins Genomics, headquartered in Luxembourg, introduced a new service package combining SMRT sequencing with comprehensive genomic annotation and reporting. This offering provides customers with an end-to-end solution for genomic projects, emphasizing Eurofins’ commitment to supporting scientific discovery and clinical research. The launch reinforces Eurofins’ expanding footprint in the global SMRT sequencing market, catering to diverse research and commercial needs

SKU-50307